Trial Profile
Single Dose, Three-way, Cross-over, Relative Bioavailability Study With 3 Oral Formulations for Hormone Replacement Therapy in Postmenopausal Women: 0.5 mg Estradiol + 0.1 mg Norethisterone Acetate, 0.5 mg Estradiol + 0.25 mg Norethisterone Acetate, and 1.0 mg Estradiol + 0.5 mg Norethisterone Acetate.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Estradiol/norethisterone (Primary)
- Indications Menopausal syndrome; Postmenopausal osteoporosis
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 26 Nov 2011 New trial record